article thumbnail

World Parkinson’s Day: New drug research

Drug Discovery World

Read more: Industry-academia partners to exploit USP30 as a therapy target Get involved in World Parkinson’s Day: [link] The post World Parkinson’s Day: New drug research appeared first on Drug Discovery World (DDW).

article thumbnail

Pfizer, looking for a jumpstart, leans into cancer drug research

BioPharma Drive: Drug Pricing

Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTC, in unusual move, leads Sanofi to terminate a drug research deal

BioPharma Drive: Drug Pricing

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

article thumbnail

FogPharma pulls in $145M to support cancer drug research

BioPharma Drive: Drug Pricing

The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.

article thumbnail

Startup Mariana raises $175M for radiopharmaceutical drug research

BioPharma Drive: Drug Pricing

The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.

article thumbnail

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Drive: Drug Pricing

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

article thumbnail

Septerna raises $150M to fuel GPCR drug research

BioPharma Drive: Drug Pricing

RA Capital led a Series B financing round that drew participation from more than a dozen blue-chip venture backers, including new investors Goldman Sachs and Vertex Ventures.